These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38155663)

  • 1. Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial.
    Oka K; Masuda T; Ohara K; Miura M; Morinari M; Misawa K; Miyazawa Y; Akimoto T; Shimada K; Nagata D
    Front Med (Lausanne); 2023; 10():1287066. PubMed ID: 38155663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease.
    Ohara K; Masuda T; Morinari M; Okada M; Miki A; Nakagawa S; Murakami T; Oka K; Asakura M; Miyazawa Y; Maeshima A; Akimoto T; Saito O; Nagata D
    Diabetol Metab Syndr; 2020; 12():37. PubMed ID: 32377235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporter 2 Inhibitor Combined with Conventional Diuretics Ameliorate Body Fluid Retention without Excessive Plasma Volume Reduction.
    Asakura-Kinoshita M; Masuda T; Oka K; Ohara K; Miura M; Morinari M; Misawa K; Miyazawa Y; Akimoto T; Shimada K; Nagata D
    Diagnostics (Basel); 2024 Jun; 14(11):. PubMed ID: 38893720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan.
    Ohara K; Masuda T; Murakami T; Imai T; Yoshizawa H; Nakagawa S; Okada M; Miki A; Myoga A; Sugase T; Sekiguchi C; Miyazawa Y; Maeshima A; Akimoto T; Saito O; Muto S; Nagata D
    Nephrology (Carlton); 2019 Sep; 24(9):904-911. PubMed ID: 30578654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats.
    Masuda T; Ohara K; Vallon V; Nagata D
    Am J Physiol Renal Physiol; 2022 Sep; 323(3):F361-F369. PubMed ID: 35900341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.
    Sen T; Scholtes R; Greasley PJ; Cherney DZI; Dekkers CCJ; Vervloet M; Danser AHJ; Barbour SJ; Karlsson C; Hammarstedt A; Li Q; Laverman GD; Bjornstad P; van Raalte DH; Heerspink HJL
    Diabetes Obes Metab; 2022 Aug; 24(8):1578-1587. PubMed ID: 35478433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy.
    Schork A; Saynisch J; Vosseler A; Jaghutriz BA; Heyne N; Peter A; Häring HU; Stefan N; Fritsche A; Artunc F
    Cardiovasc Diabetol; 2019 Apr; 18(1):46. PubMed ID: 30953516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD.
    Smeijer JD; Wasehuus VS; Dhaun N; Gorriz JL; Soler MJ; Åstrand M; Mercier AK; Greasley PJ; Ambery P; Heerspink HJL
    J Am Soc Nephrol; 2024 Jul; ():. PubMed ID: 38995699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes.
    Vart P; Vaduganathan M; Jongs N; Remuzzi G; Wheeler DC; Hou FF; McCausland F; Chertow GM; Heerspink HJL
    Clin J Am Soc Nephrol; 2022 Dec; 17(12):1754-1762. PubMed ID: 36414316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.
    Provenzano M; Puchades MJ; Garofalo C; Jongs N; D'Marco L; Andreucci M; De Nicola L; Gorriz JL; Heerspink HJL; ;
    J Am Soc Nephrol; 2022 Aug; 33(8):1569-1580. PubMed ID: 35440501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease.
    Mima A
    Adv Ther; 2021 May; 38(5):2201-2212. PubMed ID: 33860925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: The GliRACo study.
    Berton AM; Parasiliti-Caprino M; Prencipe N; Bioletto F; Lopez C; Bona C; Caputo M; Rumbolo F; Ponzetto F; Settanni F; Gasco V; Mengozzi G; Ghigo E; Grottoli S; Maccario M; Benso AS
    Front Neurosci; 2023; 17():1098404. PubMed ID: 37021137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure.
    Kaplinsky E
    Drugs Context; 2020; 9():. PubMed ID: 32165892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy.
    Daniele G; Solis-Herrera C; Dardano A; Mari A; Tura A; Giusti L; Kurumthodathu JJ; Campi B; Saba A; Bianchi AM; Tregnaghi C; Egidi MF; Abdul-Ghani M; DeFronzo R; Del Prato S
    Diabetologia; 2020 Nov; 63(11):2423-2433. PubMed ID: 32827269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.
    Sahay RK; Giri R; Shembalkar JV; Gupta SK; Mohan B; Kurmi P; Kumar SR; Sawardekar VM; Mishra A; Murthy LS; Arya VV; Sonawane AR; Soni PN; Gofne SK; Karnawat SR; Rajurkar MN; Patel PM; Lakhwani LK; Mehta SC; Joglekar SJ
    Adv Ther; 2023 Jul; 40(7):3227-3246. PubMed ID: 37258803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists.
    Provenzano M; Jongs N; Vart P; Stefánsson BV; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Toto RD; Wheeler DC; Heerspink HJL;
    Kidney Int Rep; 2022 Mar; 7(3):436-443. PubMed ID: 35257056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors.
    Eickhoff MK; Dekkers CCJ; Kramers BJ; Laverman GD; Frimodt-Møller M; Jørgensen NR; Faber J; Danser AHJ; Gansevoort RT; Rossing P; Persson F; Heerspink HJL
    J Clin Med; 2019 May; 8(6):. PubMed ID: 31159350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA-CKD Trial.
    Chertow GM; Correa-Rotter R; Vart P; Jongs N; McMurray JJV; Rossing P; Langkilde AM; Sjöström CD; Toto RD; Wheeler DC; Heerspink HJL;
    J Am Heart Assoc; 2023 May; 12(9):e028739. PubMed ID: 37119064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.